Acute Renal Failure (ARF) - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 68

Acute Renal Failure (ARF) - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Acute Renal Failure Pipeline Review, Q4 2010”, provides an overview of the Acute Renal Failure therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Renal Failure . “Acute Renal Failure -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Acute Renal Failure   .
- A review of the Acute Renal Failure    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Renal Failure    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Acute Renal Failure   .
- A review of the Acute Renal Failure    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Renal Failure    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Renal Failure (ARF) Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Renal Failure (ARF)
Acute Renal Failure (ARF) Therapeutics under Development by Companies
Acute Renal Failure (ARF) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Acute Renal Failure (ARF) Therapeutics Development
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Quark Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
BioLineRx, Ltd.
Austin Health
LEO Pharma A/S
Pfizer Inc.
Ikaria Holdings, Inc.
Theratechnologies Inc.
Am-Pharma B.V.
Angion Biomedica Corp.
Thrasos, Inc.
Exponential Biotherapies, Inc.
Omeros Corporation
Endacea, Inc.
Nephrx Corporation
Celtic Pharmaceutical Holdings L.P.
Universities/Institutes Involved in Acute Renal Failure (ARF) Therapeutics Development
Acute Renal Failure (ARF) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Heparin Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kiacta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
atorvastatin 80 mg per os daily + placebo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Corlopam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Corlopam + Mesnex for Acute Kidney Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Curcumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Chemotherapy + Plasma Exchange - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin Beta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ethanol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iloprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nesiritide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium bicarbonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium Bicarbonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sufrexal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Acute Renal Failure (ARF) - Featured News
Jul 06, 2010: Angion Biomedica Receives Fast Track And Orphan Drug Designations From FDA For BB3
Mar 10, 2010: AM-Pharma Presents Positive Results of Its Phase II Clinical Trial With Alkaline Phosphatase in Acute Kidney Injury At The ISICEM Conference In Brussels
Mar 10, 2010: Affymax Receives $5 Million Milestone Payment On Initiation Of Phase III Clinical Trials For Hematide In Japan
Jan 05, 2010: Quark Pharmaceuticals To Advance Clinical Studies of QPI-1002
Nov 23, 2009: Proteon Initiates Second Phase 1/2 Clinical Study Of PRT-201 In Hemodialysis Patients
Nov 02, 2009: Quark Pharmaceuticals To Present Data On Its siRNA Therapeutic Programs In Kidney And Lung Diseases
Jun 09, 2009: Quark Announces The Presentation Of Data Indicating Potential Utility Of QPI-1002 In Chronic Kidney Disease At The RNA Interference Summit
May 18, 2009: EBI Announces Start Of Phase II Human Clinical Trials On Renal Protection With EA-230
Mar 09, 2009: Quark Pharmaceuticals Presents at Asia TIDES Conference
Mar 03, 2009: Thrasos Therapeutics Issued U.S. Patent For First-In-Class Compounds That Selectively Target Key Receptors Of The Bone Morphogenetic Protein Pathway
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Renal Dialysis Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
• Pandemic Influenza – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Nitric Oxide - Therapeutics, Markets and Companies